Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252473 | 0.80 | TDP1 (0.48) | TDP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL57316 | 0.80 | TSHR (0.48) | TDP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL29467181 | 0.80 | TSHR (0.48) | TDP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL11797396 | 0.78 | TDP1 (0.47) | TDP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL23612111 | 0.78 | MAPT (0.42) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL8781226 | 0.77 | TDP1 (0.48) | TDP1TSHRALDH1A1CYP3A4PIN1 | |
| SCHEMBL17512681 | 0.77 | TDP1 (0.46) | TDP1TSHRALDH1A1CYP3A4PIN1 | |
| SCHEMBL15270693 | 0.77 | ALDH1A1 (0.44) | TDP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL858456 | 0.77 | TDP1 (0.46) | TDP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL381803 | 0.77 | ALDH1A1 (0.49) | TSHRALDH1A1CYP3A4PIN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103819398-B | The synthetic method of the chloro-3-nitropyridine of 4-amino-2- | HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-05-04 | — | — | CN | claimed |
| CN-103819398-A | Method for synthesizing 4-amino-2-chlorine-3-nitro pyridine | UNIV HEBEI SCIENCE & TECH | 2014-05-28 | — | — | CN | claimed |
| EP-4725493-A2 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3902806-B1 | THIENOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-07 | — | — | EP | disclosed |
| US-12398155-B2 | Thienopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-26 | — | — | US | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| WO-2025099451-A1 | NEW COMPOUNDS AND METHODS | Transition Bio Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| US-20040116466-A1 | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2004-06-17 | — | — | US | disclosed |
| WO-2004024897-A2 | PHENYL-AZA-BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1066286-A4 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-02-11 | — | — | EP | disclosed |
| EP-1066286-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-01-10 | — | — | EP | disclosed |
| US-5990109-A | NOVEL COMPOUNDS, METHODS OF THEIR SYNTHESIS, AND THEIR USE IN TREATING VARIOUS TYROSINE KINASE-ASSOCIATED IMMUNOLOGICAL DISORDERS, SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GRAFT VS. HOST DISEASE, LUPUS, PSORIASIS AND ASTHMA | BRISTOL-MYERS SQUIBB CO. (US) | 1999-11-23 | — | — | US | disclosed |
| WO-1999045009-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-10 | — | — | WO | disclosed |
| US-4652565-A | NEUROLEPTIC, HYPOTENSIVE, BRADYCARDIC | SANDOZ LTD. (CH) | 1987-03-24 | — | — | US | disclosed |
| US-4565816-A | HYPOTENSIVE, BRADYCARDIAL, NEUROLEPTIC | SANDOZ LTD. (CH) | 1986-01-21 | — | — | US | disclosed |
| WO-1983004254-A1 | PIPERAZINE DERIVATIVE COMPOUNDS, PRODUCTION METHOD THEREOF AND DRUGS CONTAINING THEM | SANDOZ AG (CH) | 1983-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | TDP1 1007/4885TSHR 3250/4885ALDH1A1 361/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | TDP1 2127/4885TSHR 182/4885ALDH1A1 877/4885 |
| US-12398155-B2 | Thienopyridinone compounds | FGFR3, FGFR1, FGFR2 | TDP1 1061/4885TSHR 375/4885ALDH1A1 1260/4885 |
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | TDP1 1618/4885TSHR 3612/4885ALDH1A1 3060/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | TDP1 4609/4885TSHR 1369/4885ALDH1A1 540/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | TDP1 1826/4885TSHR 4121/4885ALDH1A1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.